Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor

Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor

US Patent 9474754 · Granted Oct 25, 2016

Estimated economic value: $8,179,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Therapeutic combinations comprising a c-RAF inhibitor2024
Therapeutic combinations comprising a c-RAF inhibitor2024
Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers2022
Pharmaceutical combinations2022
Method of treating a proliferative disease2021
Therapeutic uses of a C-RAF inhibitor2021
Therapeutic uses of a C-RAF inhibitor2021
Combination therapy2020
Combination therapy2020
Pharmaceutical combinations2019
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF2019
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/2019